In contrast to established myeloid malignancies, such as acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), CHIP clones tend to be characterized by a more restricted range of mutations as well as a smaller clone size [8]. This evidence concerns the gene STUB1 and myelodysplastic syndrome.